Amunbio, INc.
Amunbio, INc.
  • Home
  • AmunBio Science
  • AmunBio Team
  • Investor relations
  • Media
  • Contact Us
  • More
    • Home
    • AmunBio Science
    • AmunBio Team
    • Investor relations
    • Media
    • Contact Us
  • Home
  • AmunBio Science
  • AmunBio Team
  • Investor relations
  • Media
  • Contact Us

AmunBio Team

Prem Seth, PhD, Scientific Founder

Cecilia Zapata-Harms, MS, MHA Operations

Weidong Xu, PhD, Principal Scientist

37+ years in virus research; PhD in  Biochemistry from WesternUniversity, post-  doctoral research in Dr. Ira Pastan’s lab, NCI  and was Director of the Gene Therapy  Program at NorthShore University  HealthSystem., Evanston, Il; Dr. Seth   developed several novel therapies for cancer  treatment and focused on innovative gene  therapy/immunotherapy approaches using  oncolytic viruses.

Weidong Xu, PhD, Principal Scientist

Cecilia Zapata-Harms, MS, MHA Operations

Weidong Xu, PhD, Principal Scientist

Receiving his Ph.D in Department of Molecular Physiology and Biophysics, University of Iowa, Dr. Xu explored the cross-disciplinary field of translational medicine. Becoming an expert in cancer gene therapy while working with Dr. Seth. His work has increased therapeutic efficacy of oncolytic viruses. Currently he is a principal investigator at NorthShore University Health System, a teaching affiliate of University of Chicago.

Cecilia Zapata-Harms, MS, MHA Operations

Cecilia Zapata-Harms, MS, MHA Operations

Cecilia Zapata-Harms, MS, MHA Operations

27+ years experience in life science and cancer research operations and administration. Member of the founder team, Rosetta Inpharmatics; member of the strategic development founder team, Seattle Cancer Care Alliance; division administrator of molecular pharmacology at Fred Hutchinson Cancer  Research Center and director of affiliate network, Seattle Cancer Care Alliance.

AmunBio Scientific Advisory Board

Andrei Shustov, MD

John Stewart, IV, MD, MBA

Nancy Whiting, PharmD

Expansive lead role in multiple cancer drug FDA approvals,  expert in hematologic malignancies (non-hodgkins, hodgkins  lymphomas, acute and chornic leukemias), focused on  systemic and cutaneous T-cell lymphomas; pivotal member of  the immunotherapy program at Fred Hutchinson Cancer Research Center; founder of T-cell leukemia lymphoma  foundation.

Nancy Whiting, PharmD

John Stewart, IV, MD, MBA

Nancy Whiting, PharmD

Seasoned executive and leader in drug development,  currently Executive VP and Corporate Strategy for Seattle  Genetics. Received her PharmD at the University of  Washington, Sr. Oncology Medical Scientist for GSK. Named  as top woman executive and leader in the life science  industry.

John Stewart, IV, MD, MBA

John Stewart, IV, MD, MBA

John Stewart, IV, MD, MBA

Pioneer in cellular immune therapy and  knowledge-expert on oncolytic viruses; trained  at the Rosenberg Labs; Professor of Surgery  with Tenure at University of Illinois, College of  Medicine.

Copyright © 2022 Amunbio - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept